BACKGROUND: Knowledge pertaining to the effectiveness of smoking cessation treatments and patient characteristics that may affect success may enable smokers and clinicians to select individualized treatment for each patient and ultimately increase the success rate of smoking cessation in general. OBJECTIVE: To evaluate the effectiveness of bupropion as a smoking cessation agent when used in routine clinical practice. METHODS: This was a prospective, observational study with a one year follow-up period. Adult smokers presenting to community pharmacies in British Columbia, Canada, with an index prescription for bupropion for smoking cessation (N = 205) were eligible. The primary outcome was the biochemically validated 12 month point abstinence (PA) rate from smoking. Secondary outcomes included the frequency of adverse events, patterns of bupropion use in routine clinical practice, and possible predictors of bupropion effectiveness. RESULTS: The validated 12 month PA rate was 21.0%. Of subjects who reported taking at least one dose of bupropion, 70.4% (126/179) experienced at least one adverse event and 29.6% (53/179) reported stopping the drug due to adverse effects. Greater length of time on bupropion (OR 0.98) and a lower cigarette pack-year history (OR 1.05) were associated with an increase in the odds of smoking cessation. CONCLUSIONS: Subjects receiving bupropion in a real-life setting exhibited a similar abstinence rate at 12 months as has been observed in the active drug groups of placebo-controlled clinical trials. However, the patterns of use and discontinuation rate due to adverse events differed substantially from those observed in early efficacy studies.
BACKGROUND: Knowledge pertaining to the effectiveness of smoking cessation treatments and patient characteristics that may affect success may enable smokers and clinicians to select individualized treatment for each patient and ultimately increase the success rate of smoking cessation in general. OBJECTIVE: To evaluate the effectiveness of bupropion as a smoking cessation agent when used in routine clinical practice. METHODS: This was a prospective, observational study with a one year follow-up period. Adult smokers presenting to community pharmacies in British Columbia, Canada, with an index prescription for bupropion for smoking cessation (N = 205) were eligible. The primary outcome was the biochemically validated 12 month point abstinence (PA) rate from smoking. Secondary outcomes included the frequency of adverse events, patterns of bupropion use in routine clinical practice, and possible predictors of bupropion effectiveness. RESULTS: The validated 12 month PA rate was 21.0%. Of subjects who reported taking at least one dose of bupropion, 70.4% (126/179) experienced at least one adverse event and 29.6% (53/179) reported stopping the drug due to adverse effects. Greater length of time on bupropion (OR 0.98) and a lower cigarette pack-year history (OR 1.05) were associated with an increase in the odds of smoking cessation. CONCLUSIONS: Subjects receiving bupropion in a real-life setting exhibited a similar abstinence rate at 12 months as has been observed in the active drug groups of placebo-controlled clinical trials. However, the patterns of use and discontinuation rate due to adverse events differed substantially from those observed in early efficacy studies.
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern Journal: JAMA Psychiatry Date: 2014-07-01 Impact factor: 21.596
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2013-02-21 Impact factor: 7.853
Authors: Arthur L Brody; Edythe D London; Richard E Olmstead; Zoe Allen-Martinez; Stephanie Shulenberger; Matthew R Costello; Anna L Abrams; David Scheibal; Judah Farahi; Steven Shoptaw; Mark A Mandelkern Journal: Psychiatry Res Date: 2010-08-03 Impact factor: 3.222
Authors: Christopher S Culbertson; Jennifer Bramen; Mark S Cohen; Edythe D London; Richard E Olmstead; Joanna J Gan; Matthew R Costello; Stephanie Shulenberger; Mark A Mandelkern; Arthur L Brody Journal: Arch Gen Psychiatry Date: 2011-01-03
Authors: Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Shadi Nahvi; Bryan Wu; Kimber P Richter; Steven L Bernstein; Julia H Arnsten Journal: Drug Alcohol Depend Date: 2013-01-17 Impact factor: 4.492
Authors: Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary Journal: Nicotine Tob Res Date: 2016-08-03 Impact factor: 4.244